S&P 500   3,321.75 (+0.03%)
DOW   29,186.27 (-0.03%)
QQQ   223.87 (+0.26%)
AAPL   317.70 (+0.36%)
FB   221.32 (-0.05%)
MSFT   165.70 (-0.48%)
GOOGL   1,484.17 (+0.13%)
AMZN   1,887.46 (-0.24%)
CGC   24.12 (-0.12%)
NVDA   250.05 (+0.85%)
BABA   222.37 (+0.05%)
MU   59.17 (+0.34%)
GE   11.37 (-2.49%)
TSLA   569.56 (+4.09%)
AMD   51.43 (+0.74%)
T   39.04 (+1.35%)
ACB   2.04 (+1.49%)
F   9.16 (-0.54%)
NFLX   326.00 (-3.58%)
PRI   126.65 (+0.19%)
BAC   34.36 (+0.29%)
DIS   144.01 (+0.31%)
GILD   63.43 (+1.28%)
S&P 500   3,321.75 (+0.03%)
DOW   29,186.27 (-0.03%)
QQQ   223.87 (+0.26%)
AAPL   317.70 (+0.36%)
FB   221.32 (-0.05%)
MSFT   165.70 (-0.48%)
GOOGL   1,484.17 (+0.13%)
AMZN   1,887.46 (-0.24%)
CGC   24.12 (-0.12%)
NVDA   250.05 (+0.85%)
BABA   222.37 (+0.05%)
MU   59.17 (+0.34%)
GE   11.37 (-2.49%)
TSLA   569.56 (+4.09%)
AMD   51.43 (+0.74%)
T   39.04 (+1.35%)
ACB   2.04 (+1.49%)
F   9.16 (-0.54%)
NFLX   326.00 (-3.58%)
PRI   126.65 (+0.19%)
BAC   34.36 (+0.29%)
DIS   144.01 (+0.31%)
GILD   63.43 (+1.28%)
S&P 500   3,321.75 (+0.03%)
DOW   29,186.27 (-0.03%)
QQQ   223.87 (+0.26%)
AAPL   317.70 (+0.36%)
FB   221.32 (-0.05%)
MSFT   165.70 (-0.48%)
GOOGL   1,484.17 (+0.13%)
AMZN   1,887.46 (-0.24%)
CGC   24.12 (-0.12%)
NVDA   250.05 (+0.85%)
BABA   222.37 (+0.05%)
MU   59.17 (+0.34%)
GE   11.37 (-2.49%)
TSLA   569.56 (+4.09%)
AMD   51.43 (+0.74%)
T   39.04 (+1.35%)
ACB   2.04 (+1.49%)
F   9.16 (-0.54%)
NFLX   326.00 (-3.58%)
PRI   126.65 (+0.19%)
BAC   34.36 (+0.29%)
DIS   144.01 (+0.31%)
GILD   63.43 (+1.28%)
S&P 500   3,321.75 (+0.03%)
DOW   29,186.27 (-0.03%)
QQQ   223.87 (+0.26%)
AAPL   317.70 (+0.36%)
FB   221.32 (-0.05%)
MSFT   165.70 (-0.48%)
GOOGL   1,484.17 (+0.13%)
AMZN   1,887.46 (-0.24%)
CGC   24.12 (-0.12%)
NVDA   250.05 (+0.85%)
BABA   222.37 (+0.05%)
MU   59.17 (+0.34%)
GE   11.37 (-2.49%)
TSLA   569.56 (+4.09%)
AMD   51.43 (+0.74%)
T   39.04 (+1.35%)
ACB   2.04 (+1.49%)
F   9.16 (-0.54%)
NFLX   326.00 (-3.58%)
PRI   126.65 (+0.19%)
BAC   34.36 (+0.29%)
DIS   144.01 (+0.31%)
GILD   63.43 (+1.28%)
Log in
(Ad)
If you're looking to potentially make 1,000% in gains, then you NEED this biotech stock. This company discovered a medical breakthrough that may end heart attacks FOREVER! Estimated annual sales are $60 billion. The FDA has all but said it's going to approve the drug. Once that happens, the stock price could double overnight. But you must be onboard BEFORE FDA approval.

Audentes Therapeutics News Headlines (NASDAQ:BOLD)

$59.97
0.00 (0.00 %)
(As of 01/22/2020 04:00 PM ET)
Today's Range
$59.97
Now: $59.97
$59.97
50-Day Range
$59.20
MA: $59.70
$60.00
52-Week Range
$22.00
Now: $59.97
$60.00
VolumeN/A
Average Volume1.50 million shs
Market Capitalization$2.77 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.18

Headlines

Audentes Therapeutics (NASDAQ BOLD) News Headlines

Source:
DateHeadline
Audentes Therapeutics (BOLD) "Hold" Rating Reaffirmed at Chardan CapitalAudentes Therapeutics' (BOLD) "Hold" Rating Reaffirmed at Chardan Capital
www.americanbankingnews.com - January 20 at 7:54 AM
Zacks: Analysts Anticipate Audentes Therapeutics Inc (NASDAQ:BOLD) Will Announce Earnings of -$1.02 Per ShareZacks: Analysts Anticipate Audentes Therapeutics Inc (NASDAQ:BOLD) Will Announce Earnings of -$1.02 Per Share
www.americanbankingnews.com - January 16 at 12:22 AM
2019 Review: Most Favored Hedge Fund Stocks vs. Audentes Therapeutics, Inc. (BOLD)2019 Review: Most Favored Hedge Fund Stocks vs. Audentes Therapeutics, Inc. (BOLD)
finance.yahoo.com - January 12 at 9:43 PM
Agenus Initiates Phase I Study on Oncology Candidate AGEN1223Agenus Initiates Phase I Study on Oncology Candidate AGEN1223
finance.yahoo.com - January 9 at 3:48 PM
Audentes Therapeutics Inc (NASDAQ:BOLD) Given Consensus Recommendation of "Hold" by AnalystsAudentes Therapeutics Inc (NASDAQ:BOLD) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - January 6 at 3:28 AM
STOCKHOLDER ALERT: Monteverde & Associates PC Remind Investors of its Ongoing Investigation Regarding the AcquisitionSTOCKHOLDER ALERT: Monteverde & Associates PC Remind Investors of its Ongoing Investigation Regarding the Acquisition
finance.yahoo.com - January 3 at 3:35 PM
SHAREHOLDER NOTICE: Brodsky & Smith, LLC Reminds Investors of Investigations Related to the Following Companies: CBPX, BOLD, THORSHAREHOLDER NOTICE: Brodsky & Smith, LLC Reminds Investors of Investigations Related to the Following Companies: CBPX, BOLD, THOR
finance.yahoo.com - January 2 at 9:28 PM
Big exec payouts, lawsuits mark gene therapy companys $3.1 billion merger dealBig exec payouts, lawsuits mark gene therapy company's $3.1 billion merger deal
www.bizjournals.com - December 31 at 9:47 PM
Big exec payouts, lawsuits mark gene therapy company's $3.1 billion merger dealBig exec payouts, lawsuits mark gene therapy company's $3.1 billion merger deal
finance.yahoo.com - December 31 at 9:47 PM
Astellas ramps up M&A, buys U.S. biotech Xyphos for as much as $665 millionAstellas ramps up M&A, buys U.S. biotech Xyphos for as much as $665 million
finance.yahoo.com - December 27 at 12:11 AM
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders - BOLD, AKS, INST, THORSHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders - BOLD, AKS, INST, THOR
www.marketwatch.com - December 16 at 8:45 AM
SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Audentes Therapeutics, Inc. - (NasdaqGS: BOLD)SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Audentes Therapeutics, Inc. - (NasdaqGS: BOLD)
finance.yahoo.com - December 10 at 7:27 PM
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders - INST, AKS, BOLD, SORLSHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders - INST, AKS, BOLD, SORL
www.marketwatch.com - December 10 at 2:26 PM
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Audentes Therapeutics, Inc. - BOLDSHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Audentes Therapeutics, Inc. - BOLD
finance.yahoo.com - December 6 at 8:11 PM
Hedge Funds Are Souring On Audentes Therapeutics, Inc. (BOLD)Hedge Funds Are Souring On Audentes Therapeutics, Inc. (BOLD)
finance.yahoo.com - December 6 at 3:10 PM
Astellas-Audentes Deal Likely to Ignite More AcquisitionsAstellas-Audentes Deal Likely to Ignite More Acquisitions
finance.yahoo.com - December 5 at 5:26 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Audentes Therapeutics, Inc. to Astellas Pharma Inc. is Fair to ShareholdersSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Audentes Therapeutics, Inc. to Astellas Pharma Inc. is Fair to Shareholders
finance.yahoo.com - December 4 at 2:40 PM
BOLD Audentes Therapeutics, Inc. Common StockBOLD Audentes Therapeutics, Inc. Common Stock
www.nasdaq.com - December 4 at 9:39 AM
Gene Therapy M&A Appetite Provides Lift After Audentes DealGene Therapy M&A Appetite Provides Lift After Audentes Deal
www.bloomberg.com - December 3 at 11:06 PM
Why Lands End, Audentes Therapeutics, and ViewRay Jumped TodayWhy Lands' End, Audentes Therapeutics, and ViewRay Jumped Today
www.fool.com - December 3 at 6:05 PM
Why Audentes Therapeutics Stock Is Skyrocketing TodayWhy Audentes Therapeutics Stock Is Skyrocketing Today
www.fool.com - December 3 at 6:05 PM
Japans Astellas To Buy Gene Therapy Company Audentes For $3B CashJapan's Astellas To Buy Gene Therapy Company Audentes For $3B Cash
www.benzinga.com - December 3 at 1:05 PM
Are Audentes Shareholders Getting Enough in the Acquisition?Are Audentes Shareholders Getting Enough in the Acquisition?
247wallst.com - December 3 at 1:05 PM
CBL, CARA, VRAY and BOLD among midday moversCBL, CARA, VRAY and BOLD among midday movers
seekingalpha.com - December 3 at 1:05 PM
Gene-Therapy Firm Audentes Sells for Double Its Share Price. It Could Be the First of Many More Deals.Gene-Therapy Firm Audentes Sells for Double Its Share Price. It Could Be the First of Many More Deals.
www.barrons.com - December 3 at 1:05 PM
Audentes Therapeutics Soars on Astellas Pharmas $3 Billion PurchaseAudentes Therapeutics Soars on Astellas Pharma's $3 Billion Purchase
www.thestreet.com - December 3 at 1:05 PM
This Gene Therapy Stock Just Netted A $3 Billion Bid — Who's Next?This Gene Therapy Stock Just Netted A $3 Billion Bid — Who's Next?
finance.yahoo.com - December 3 at 1:05 PM
AUDENTES ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of BOLD and Encourages Investors to Contact the FirmAUDENTES ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of BOLD and Encourages Investors to Contact the Firm
finance.yahoo.com - December 3 at 1:05 PM
Japans Astellas Pharma to buy Audentes for $3 billion in gene therapy pushJapan's Astellas Pharma to buy Audentes for $3 billion in gene therapy push
www.reuters.com - December 3 at 8:05 AM
Audentes Merger Investigation: Halper Sadeh LLP...Audentes Merger Investigation: Halper Sadeh LLP...
www.benzinga.com - December 3 at 8:05 AM
Astellas Pharma to buy Audentes Therapeutics for $60/shareAstellas Pharma to buy Audentes Therapeutics for $60/share
seekingalpha.com - December 3 at 8:05 AM
Audentes Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Audentes Therapeutics, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – BOLDAudentes Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Audentes Therapeutics, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – BOLD
finance.yahoo.com - December 3 at 12:04 AM
Japans Astellas Pharma to buy Audentes Therapeutics for $3 blnJapan's Astellas Pharma to buy Audentes Therapeutics for $3 bln
www.cnbc.com - December 2 at 7:03 PM
CORRECTED-Japans Astellas Pharma to buy Audentes Therapeutics for $2.7 blnCORRECTED-Japan's Astellas Pharma to buy Audentes Therapeutics for $2.7 bln
www.cnbc.com - December 2 at 7:03 PM
Japans Astellas Pharma to buy Audentes Therapeutics for $2.7 billionJapan's Astellas Pharma to buy Audentes Therapeutics for $2.7 billion
www.reuters.com - December 2 at 7:03 PM
Astellas Enters into Definitive Agreement to Acquire Audentes TherapeuticsAstellas Enters into Definitive Agreement to Acquire Audentes Therapeutics
www.businesswire.com - December 2 at 7:03 PM
Edited Transcript of BOLD earnings conference call or presentation 7-Nov-19 9:30pm GMTEdited Transcript of BOLD earnings conference call or presentation 7-Nov-19 9:30pm GMT
finance.yahoo.com - November 21 at 9:17 AM
Audentes Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate UpdateAudentes Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update
finance.yahoo.com - November 7 at 5:49 PM
Audentes Therapeutics Q3 2019 Earnings PreviewAudentes Therapeutics Q3 2019 Earnings Preview
seekingalpha.com - November 7 at 7:32 AM
Audentes Therapeutics to Release Third Quarter 2019 Financial Results and Provide Corporate Update on Thursday, November 7, 2019Audentes Therapeutics to Release Third Quarter 2019 Financial Results and Provide Corporate Update on Thursday, November 7, 2019
finance.yahoo.com - October 31 at 9:11 AM
Audentes Therapeutics Presents New Positive Data from ASPIRO, the Clinical Trial Evaluating AT132 in Patients with X-Linked Myotubular Myopathy (XLMTM), at the 24th International Annual Congress of the World Muscle SocietyAudentes Therapeutics Presents New Positive Data from ASPIRO, the Clinical Trial Evaluating AT132 in Patients with X-Linked Myotubular Myopathy (XLMTM), at the 24th International Annual Congress of the World Muscle Society
finance.yahoo.com - October 16 at 10:20 PM
Audentes Therapeutics (BOLD) Presents At 24th International Annual Congress of the World Muscle Society - SlideshowAudentes Therapeutics (BOLD) Presents At 24th International Annual Congress of the World Muscle Society - Slideshow
seekingalpha.com - October 8 at 3:44 PM
Audentes Announces Upcoming Presentations at the 24th International Annual Congress of the World Muscle Society, Including New Data From ASPIRO, the Clinical Trial Evaluating AT132 in Patients With X-Linked Myotubular Myopathy (XLMTM)Audentes Announces Upcoming Presentations at the 24th International Annual Congress of the World Muscle Society, Including New Data From ASPIRO, the Clinical Trial Evaluating AT132 in Patients With X-Linked Myotubular Myopathy (XLMTM)
finance.yahoo.com - September 30 at 8:17 AM
Have Insiders Been Selling Audentes Therapeutics, Inc. (NASDAQ:BOLD) Shares?Have Insiders Been Selling Audentes Therapeutics, Inc. (NASDAQ:BOLD) Shares?
finance.yahoo.com - September 19 at 12:58 PM
Oversold Conditions For Audentes Therapeutics (BOLD)Oversold Conditions For Audentes Therapeutics (BOLD)
www.nasdaq.com - September 5 at 10:24 AM
Solid Biosciences Surges on DMD Gene Therapy Study AmendmentsSolid Biosciences Surges on DMD Gene Therapy Study Amendments
finance.yahoo.com - August 19 at 10:04 AM
Why Audentes rAAV Gene Therapy Can Be A Game ChangerWhy Audentes' rAAV Gene Therapy Can Be A Game Changer
seekingalpha.com - August 9 at 5:44 PM
Edited Transcript of BOLD earnings conference call or presentation 6-Aug-19 8:30pm GMTEdited Transcript of BOLD earnings conference call or presentation 6-Aug-19 8:30pm GMT
finance.yahoo.com - August 9 at 5:43 PM
Audentes Therapeutics, Inc. (BOLD) Q2 2019 Earnings Call TranscriptAudentes Therapeutics, Inc. (BOLD) Q2 2019 Earnings Call Transcript
finance.yahoo.com - August 7 at 11:28 AM
Audentes Therapeutics EPS beats by $0.06Audentes Therapeutics EPS beats by $0.06
seekingalpha.com - August 6 at 5:45 PM
This page was last updated on 1/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel